Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma

NCT02448381 is registered in ClinicalTrials.gov with Soligenix as lead sponsor.

NCT NCT02448381
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02448381 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma
Lead sponsor
Soligenix
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2015
Completion date
November 30, 2020
Enrollment
169 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous t-cell lymphoma